What we know about the Moderna Covid-19 vaccine
The Moderna coronavirus vaccine is the third jab to be rolled out in the UK.
It will be administered to people in Wales from Wednesday.
It follows the rollout of the Pfizer and AstraZeneca vaccines, which began in December and January respectively.
Here’s what we know about the Moderna vaccine.
- How effective is it against coronavirus?
The phase three results suggested vaccine efficacy against the disease was 94.1%, and vaccine efficacy against severe Covid-19 was 100%.
More than 30,000 people in the US took part in the trial, from a wide range of age groups and ethnic backgrounds.
Two doses were given 28 days apart so researchers could evaluate safety and any reaction to the vaccine.
The analysis was based on 196 cases, of which 185 cases of Covid-19 were observed in the placebo group versus 11 cases observed in the active vaccine group.
Moderna also released data relating to severe cases.
All 30 severe cases occurred in the placebo group and none in the group which had received the vaccine, known as mRNA-1273.
Subscribe to the Evening Standard on USworlds: usworlds.info/tv/7RQon_YwCnp_LbPtEwW65w